Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 5/20 | 0.34 |
| ▸ | MTTP | P55157 | 8/20 | 0.33 |
| ▸ | APOB | P04114 | 7/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500413 | 0.92 | TP53 (0.35) | CYP17A1HDAC6HDAC1 | |
| SCHEMBL6500169 | 0.91 | DGAT1 (0.34) | RXFP1HDAC6HDAC1SMOMTTP | |
| SCHEMBL6487517 | 0.87 | TP53 (0.39) | HDAC6HDAC1 | |
| SCHEMBL6792697 | 0.85 | MTTP (0.45) | RXFP1SMOMTTPAPOB | |
| SCHEMBL6498208 | 0.85 | CYP17A1 (0.37) | CYP17A1HDAC6HDAC1 | |
| SCHEMBL6490538 | 0.85 | CHRNB2 (0.38) | RXFP1CYP17A1SMOMTTPAPOB | |
| SCHEMBL6501309 | 0.83 | TP53 (0.34) | CYP17A1HDAC6HDAC1 | |
| SCHEMBL6490132 | 0.81 | LCK (0.39) | — | |
| SCHEMBL6499810 | 0.80 | CTNNB1 (0.38) | — | |
| SCHEMBL6487457 | 0.80 | DRD2 (0.47) | SMOMTTPAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | RXFP1 1851/4885CYP17A1 1340/4885HDAC6 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.